Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

This study has suspended participant recruitment.
(Clinical hold enacted due to increased risk of blood clot.)
Sponsor:
Information provided by (Responsible Party):
Peter S. Hammerman, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01761747
First received: September 26, 2012
Last updated: October 22, 2013
Last verified: October 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)